{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:26:32Z","timestamp":1791134792944,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T00:00:00Z","timestamp":1418428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.leukres.2014.11.027","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:31:34Z","timestamp":1418085094000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"Harry P.","family":"Erba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.11.027_bib0005","unstructured":"National Cancer Institute. Cancer Statistics Review 1975\u20132003: Table I\u201311 median age of cancer patients at diagnosis, 2000\u20132003 by primary cancer site, race and sex. Available at: \u3008http:\/\/seer.cancer.gov\/archive\/csr\/1975_2003\/results_single\/sect_01_table.11_2pgs.pdf\u3009 (accessed: October 2013)."},{"key":"10.1016\/j.leukres.2014.11.027_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.leukres.2014.11.027_bib0015","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0020","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","article-title":"The outcomes and costs of acute myeloid leukemia among the elderly","volume":"162","author":"Menzin","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.leukres.2014.11.027_bib0025","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1002\/cncr.25281","article-title":"Questions regarding frontline therapy of acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2001.1.62","article-title":"Acute myeloid leukemia","volume":"6","author":"Appelbaum","year":"2001","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2014.11.027_bib0035","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. Acute myeloid leukemia. Version 2. Available at: \u3008http:\/\/www.nccn.org\u3009 (accessed: October 2013)."},{"key":"10.1016\/j.leukres.2014.11.027_bib0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0045","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0050","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0055","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.beha.2010.09.012","article-title":"Has there been progress in the treatment of older patients with acute myeloid leukemia","volume":"23","author":"Erba","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0065","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0070","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019 induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.11.027_bib0080","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0085","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0090","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2010-01-267302","article-title":"A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial","volume":"116","author":"Rollig","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0095","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1200\/JCO.2013.52.3480","article-title":"Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia","volume":"32","author":"Pastore","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2014.11.027_bib0110","doi-asserted-by":"crossref","first-page":"e2013050","DOI":"10.4084\/mjhid.2013.050","article-title":"Therapeutic options for patients who are not eligible for intensive chemotherapy","volume":"5","author":"Estey","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.leukres.2014.11.027_bib0115","first-page":"788","article-title":"Results of a phase 3, multicenter, randomized, open-label study of azacitidine (AZA) vs conventional care regimens (CCR) in older patients with newly diagnosed acute myeloid leukemia (AML)","volume":"99","author":"Dombret","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.11.027_bib0120","unstructured":"Astex Pharmaceuticals Inc. Press release: DACOGEN(R) approved in the European Union for the treatment of acute myeloid leukemia. Available at: \u3008http:\/\/astx.com\/content\/resources\/ASTX_News_2012_7_20_General_Releases.pdf\u3009 (accessed: August 2014)."},{"key":"10.1016\/j.leukres.2014.11.027_bib0125","unstructured":"Astex Pharmaceuticals Inc. Press release: FDA's Oncologic Drugs Advisory Committee (ODAC) votes to not support benefit\/risk profile of Dacogen\u00ae (decitabine) in acute myeloid leukemia. Available at: \u3008http:\/\/astx.com\/content\/resources\/ASTX_News_2012_2_9_General_Releases.pdf\u3009 (accessed: October 2013)."},{"key":"10.1016\/j.leukres.2014.11.027_bib0130","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review: azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2014.11.027_bib0140","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.2012.44.2962","article-title":"Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia","volume":"30","author":"Sekeres","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.1990.8.2.272","article-title":"Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly","volume":"8","author":"Tilly","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0150","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0155","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2007-02-073700","article-title":"AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0160","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.11791","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"98","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0165","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1158\/0008-5472.CAN-05-0288","article-title":"Molecular basis for G2 arrest induced by 2\u2032-C-cyano-2\u2032-deoxy-1-beta-d-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.11.027_bib0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.2012.660249","article-title":"Sapacitabine for cancer","volume":"21","author":"Liu","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.leukres.2014.11.027_bib0175","first-page":"415","article-title":"Tipifarnib in the treatment of acute myeloid leukemia","volume":"1","author":"Thomas","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.leukres.2014.11.027_bib0180","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","article-title":"BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity","volume":"15","author":"Rudolph","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.11.027_bib0185","first-page":"841","article-title":"PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2014.11.027_bib0190","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","article-title":"Discovery and development of clofarabine: a nucleoside analogue for treating cancer","volume":"5","author":"Bonate","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2014.11.027_bib0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0200","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/0008-5472.CAN-07-6627","article-title":"CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells","volume":"68","author":"Krige","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.11.027_bib0205","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0210","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2014.11.027_bib0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OTT.S21957","article-title":"Hedgehog pathway as a drug target: smoothened inhibitors in development","volume":"5","author":"Lin","year":"2012","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.leukres.2014.11.027_bib0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.leukres.2014.11.027_bib0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.11.027_bib0230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09165.x","article-title":"The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML","volume":"158","author":"Burnett","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0235","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0240","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.clml.2013.03.019","article-title":"Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.leukres.2014.11.027_bib0245","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.28113","article-title":"Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2014.11.027_bib0250","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3630.3630","article-title":"Phase 1\/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed AML","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0255","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2630.2630","article-title":"Pooled analysis of elderly patients with newly diagnosed AML treated with sapacitabine and decitabine administered in alternating cycles","volume":"120","author":"Ravandi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0260","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0265","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.6502","volume":"30","author":"Nand","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0270","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood-2013-06-506592","article-title":"A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia","volume":"122","author":"Nand","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0275","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3324\/haematol.2012.076414","article-title":"Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia","volume":"98","author":"Pollyea","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2014.11.027_bib0280","volume":"118","author":"Garcia-Manero","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0285","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(13)70037-8","article-title":"Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study","volume":"14","author":"Cortes","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2014.11.027_bib0290","unstructured":"CTI issues statement regarding tosedostat clinical trial. Available at: \u3008http:\/\/investors.celltherapeutics.com\/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1832542\u3009 (accessed: October 2013)."},{"key":"10.1016\/j.leukres.2014.11.027_bib0295","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Blum","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.11.027_bib0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1868-7083-5-13","article-title":"The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.leukres.2014.11.027_bib0305","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2010.1.62","article-title":"Treating the elderly patient with acute myelogenous leukemia","volume":"2010","author":"Luger","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.leukres.2014.11.027_bib0310","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.3816\/CLM.2009.s.027","article-title":"What are the endpoints of therapy for acute leukemias? Old definitions and new challenges","volume":"9","author":"Smith","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.leukres.2014.11.027_bib0315","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T18:03:24Z","timestamp":1598551404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614003798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0145212614003798"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.11.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}